Table 3 Summary quality assessment of included studies
Quality criterion | Studies (n, %) | ||
|---|---|---|---|
Yes | No | Unclear | |
Economic component | |||
 Data sources for expenditure, resource use and unit costs were clearly explained | 48 (58%) | 34 (42%) | n/a |
 Cost and/or productivity data were transparently presented | 24 (29%) | 59 (71%) | n/a |
 Productivity costs were included | 23 (28%) | 60 (72%) | 0 (0%) |
 If productivity costs included, results were presented with and without productivity costs | 20 (24%) | 3 (4%) | n/a |
 The analysis addressed uncertainty and/or heterogeneity | 53 (64%) | 30 (36%) | 0 (0%) |
Epidemiologic component | |||
 The source of incidence/prevalence data contributed to the study’s internal validity | 35 (42%) | 13 (16%) | 28 (34%) |
 The patient sampling method appropriate for deriving nationwide estimates of incidence/prevalence | 21 (25%) | 49 (58%) | 9 (11%) |